ClinicalTrials.gg
RecruitingNCT06843356RESCUE-BAOUpdated Sep 16, 2026

Rescue Endovascular Treatment After Neurological Deterioration in Initially Mild Basilar Artery Occlusion in an Extended Time Window

An interventional study of Endovascular Treatment in Acute Mild Ischemic Stroke, Basilar Artery Occlusion and Rescue Endovascular Treatment, sponsored by First Affiliated Hospital of Wannan Medical College. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by First Affiliated Hospital of Wannan Medical College · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Planned enrollment
366th of 566
159 · median 271
Started
2025
with 106 others
No phase
247 of 754
122 open now
Primary completion
2027-09
later than 228 of 399 live
Registered
535th of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one is the 366th largest by planned enrollment of the 566 interventional ones that give a count, is one of 107 that started in 2025, is one of 247 with no phase, reaches primary completion later than 228 of the 399 other live ones, and was the 535th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

376 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

A prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial to evaluate whether best medical management (BMM) combined with endovascular therapy (EVT) improves neurological outcomes compared to BMM alone in patients with progressive acute mild ischemic stroke due to basilar artery occlusion within an extended time window.

Read the detailed description

This trial aims to evaluate whether best medical management (BMM) combined with endovascular therapy (EVT) improves neurological outcomes compared to BMM alone in patients with progressive acute mild ischemic stroke due to basilar artery occlusion within an extended time window. The study used a stratified block randomization method. A central randomization system was used to assign subjects to the experimental group and the control group in a 2:1 ratio for each center.

03

Conditions studied

  • Acute Mild Ischemic Stroke
  • Basilar Artery Occlusion
  • Rescue Endovascular Treatment
  • Extended Time Window

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. Initially mild ischemic stroke, defined as an initial NIHSS score \<6, with no prior endovascular treatment for the index ischemic event.
  3. Basilar artery occlusion, or vertebral artery occlusion resulting in complete interruption of antegrade flow into the basilar artery, documented by CTA, MRA, or DSA during the initially mild phase and before qualifying neurological deterioration.
  4. Qualifying neurological deterioration occurring between 24 hours and 7 days after initial symptom onset, or after the last known well if symptom onset is unknown.
  5. Qualifying neurological deterioration is defined as an NIHSS score ≥10 with either a ≥4-point increase in total NIHSS or a ≥2-point increase in the NIHSS level-of-consciousness score from the initial NIHSS score and must be documented by certified medical personnel at a medical facility, including a referring hospital.
  6. Posterior circulation Acute Stroke Prognosis Early CT Score (pc-ASPECTS) ≥6 on noncontrast CT or diffusion-weighted MRI performed after qualifying neurological deterioration.
  7. Time from qualifying neurological deterioration to randomization ≤24 hours.
  8. Written obtained from the patient or a legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  1. Symptom progression due to intracranial hemorrhage, brain edema, or other clear causes (including but not limited to infarct hemorrhagic transformation, new infarction in non-occluded vascular regions, obstructive hydrocephalus, severe infection, high fever, heart or kidney dysfunction, hypovolemia, or severe electrolyte disturbances).
  2. prestroke mRS >2.
  3. Factors in the target vessel that are expected to prevent completion of endovascular treatment.
  4. Concurrent anterior and posterior circulation strokes.
  5. Prior imaging confirmed or investigator-assessed chronic basilar artery occlusion.
  6. Presence of untreated intracranial aneurysms, intracranial tumors (except small meningiomas), or intracranial vascular malformations.
  7. Intracranial hemorrhage within the past 6 months, including parenchymal brain hemorrhage, intraventricular hemorrhage, or subarachnoid hemorrhage.
  8. Gastrointestinal or urinary tract bleeding, acute myocardial infarction, cranial trauma, or major surgery within the past month.
  9. Presence of active bleeding, coagulation disorders, or uncorrectable bleeding tendencies.
  10. count \<40×10\^9/L, or >2 during anticoagulation therapy (irreversible).
  11. Severe heart, liver, or kidney dysfunction or other severe systemic late-stage diseases.
  12. Known allergy to iodine contrast agents or other treatment-related drugs.
  13. Medically uncontrolled hypertension (defined as persistent systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg) (Note: Participants can be included if their blood pressure is controllable with medication and maintained at an acceptable level).
  14. Uncontrollable blood glucose \<2.8 mmol/L or >22.2 mmol/L.
  15. Pregnancy or breastfeeding.
  16. \<6 months.
  17. Participation in other clinical studies that may affect outcome assessment.
  18. Investigator's judgment that the patient is unsuitable for participation in this study or may face significant risks (e.g., due to mental illness, cognitive, or emotional disorders preventing understanding and/or compliance with study procedures and/or follow-up).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
159 participants (estimated)

Study arms

  • Experimental
    Endovascular Therapy Group

    Researchers can choose to deal with the stenosis or occlusion of blood vessels according to their own judgment, including stent thrombectomy, thrombus aspiration, balloon angioplasty, stent replacement, intra-arterial thrombolysis or various combinations of these methods.

    Procedure: Endovascular Treatment

  • No intervention
    Best Medical Management Group

    Participants receive best medical management only. Best Medical Treatment and maximum supportive care according to local guidelines, not including mechanical thrombectomy, no intra-arterial treatment.

Interventions

  • ProcedureEndovascular Treatment

    Neurointerventionist determine whether to proceed with interventional therapy after assessing the location and degree of occlusion, the tortuosity of the access vessel, and the presence of stenosis or occlusion in the proximal artery. In cases where there is no proximal stenosis or occlusion, mechanical thrombectomy is performed, and the specific thrombectomy strategy is tailored by the researcher based on the patient's condition. For lesions associated with proximal vascular stenosis or occlusion, it is necessary to navigate the catheter through the proximal stenosis or occlusion to access the intracranial occlusion. Researchers have the discretion to treat the stenotic or occluded vessels, which may include options such as no treatment, stent thrombectomy, thrombus aspiration, balloon angioplasty, stent replacement, intra-arterial thrombolysis or various combinations of these methods.

06

What researchers measure

Primary outcomes

  1. Proportion of patients with a modified Rankin Scale (mRS) score of 0-3 at 90 (±7) days after randomization.

    The modified Rankin Score is an ordinal hierarchical scale ranging from 0 to 6, with higher scores indicating more severe disability.

    Time frame: 90 (±7)days after randomization

Secondary outcomes

  1. Shift analysis of the improvement trend in modified Rankin Scale (mRS) scores at 90 (±7) days after randomization.

    Shift analysis is a statistical method used to evaluate the overall distribution change in modified Rankin Scale (mRS) scores, assessing whether an intervention leads to a general shift toward better outcomes across all score categories.

    Time frame: 90 (±7) days after randomization

  2. Proportion of patients with a modified Rankin Scale (mRS) score of 0-2 at 90 (±7) days after randomization.

    The modified Rankin Score is an ordinal hierarchical scale ranging from 0 to 6, with higher scores indicating more severe disability.

    Time frame: 90 (±7) days after randomization

  3. Change in NIHSS score from pre-randomization baseline at 24 hours after randomization.

    The NIHSS (National Institutes of Health Stroke Scale) is a tool used to assess the severity of stroke symptoms by evaluating various neurological functions, such as consciousness, vision, movement, and speech. The score helps in gauging the degree of impairment caused by a stroke.

    Time frame: 24 hours after randomization

  4. EQ-5D-5L scale at 90 (±7) days after randomization.

    The EQ-5D-5L scale is a standardized tool used to measure a person's health-related quality of life. It includes five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each with five levels to indicate the severity of problems in those areas.

    Time frame: 90 (±7) days after randomization

  5. Change in NIHSS score from pre-randomization baseline at 7±1 days after randomization or discharge.

    The NIHSS (National Institutes of Health Stroke Scale) is a tool used to assess the severity of stroke symptoms by evaluating various neurological functions, such as consciousness, vision, movement, and speech. The score helps in gauging the degree of impairment caused by a stroke.

    Time frame: Discharge or 7±1 days after randomization

  6. Successful reperfusion postoperatively.

    The eTICI (extended Thrombolysis in Cerebral Infarction) score is a standard used to evaluate the degree of reperfusion in acute ischemic stroke patients following endovascular therapy (EVT). It is a further refinement of the mTICI (modified TICI) score.

    Time frame: At the end of the operation

Other outcomes

  1. Incidence of symptomatic intracerebral haemorrhage (sICH) within 48 hours after randomization (Heidelberg bleeding classification).

    Intracranial hemorrhage (ICH) was assessed with the Heidelberg Bleeding Classification within 48 hours of endovascular treatment. Intracranial hemorrhage was classified as hemorrhagic infarction or parenchymal hematoma. The sICH was defined as ICH associated with a worsening of 4 or more points on the NIHSS or resulting in death, and cerebral herniation, which were not present at baseline.

    Time frame: Within 48 hours after randomization.

  2. Incidence of any intracerebral haemorrhage within 48 hours after randomization (Heidelberg bleeding classification).

    Intracranial hemorrhage (ICH) was assessed with the Heidelberg Bleeding Classification within 48 hours of endovascular treatment. Intracranial hemorrhage was classified as hemorrhagic infarction or parenchymal hematoma.

    Time frame: within 48 hours after randomization

  3. All-cause mortality at 90 (±7) days after randomization.

    All-cause mortality refers to the rate of death from any cause within a specific time period, without considering the underlying cause of death.

    Time frame: 90 (±7) days after randomization

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Sep 2027, 25 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 25 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Feb 24, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06843356
Lead sponsor
First Affiliated Hospital of Wannan Medical College
Collaborators
The First Affiliated Hospital of the University of Science and Technology of China, First People's Hospital of Yulin, THE SECOND PEOPLE'S HOSPITAL, WUHU, People's Hospital of Guoyang County, Heyuan Shenhe People's Hospital, The First Affiliated Hospital of Hainan Medical University, Wuwei City People's Hospital, People's Hospital of Lixin Country, Zhongshan Hospital Of Traditional Chinese Medicine, Xihua People's Hospital, Wuhan No.1 Hospital, The Fourth Hospital of Liuan, Huaibei Miner General Hospital, Huaibei, China., Guangdong Second Provincial General Hospital, The First Affiliated Hospital of University of South China, Maoming Hospital of Traditional Chinese Medicine, People's Hospital of Linquan County, Jiangsu Province Hospital of Traditional Chinese Medicine, Haiyan People's Hospital, Haiyan County People's Hospital, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Yingshang County People's Hospital, The second affiliated hospital of Xuzhou medical university, The Central Hospital of Wuhan, Wuhan, Hubei, China, Suixi County Hospital of Traditional Chinese Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Xiangtan Central Hospital, Xiangtan, Hunan, China, Feidong County Hospital of Traditional Chinese Medicine, Hefei, Anhui, China, Dongguan People's Hospital, Dongguan, Guangdong, China
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Aug 1, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 16, 2026

Study contacts

Xianjun Huang, PhD
Contact
doctorhuangxj@hotmail.com
8618130333940
Wen Sun, PhD
Contact
sunwen_medneuro@163.com
8615050589620

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion